%0 Journal Article %A Madhusudhanan Narasimhan %A Lenin Mahimainathan %A Andrew E. Clark %A Amena Usmani %A Jing Cao %A Ellen Araj %A Fernando Torres %A Ravi Sarode %A Vaidehi Kaza %A Chantale Lacelle %A Alagarraju Muthukumar %T Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines %D 2021 %R 10.1101/2021.04.26.21255926 %J medRxiv %P 2021.04.26.21255926 %X The immunological effectiveness of SARS-CoV-2 mRNA vaccines in lung transplant (LT) recipients is largely unknown. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines’ two-dose (2D) regimen on humoral responses in immunocompromised lung transplant (LT) recipients. About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated positive spike-IgG response following 2D of vaccines, with 36% (9/25) in the Moderna cohort and only 19% (9/48) in the Pfizer cohort. 2D in LT patients elicited significantly lesser median IgGSP response (1.7 AU/mL, 95% CI: 0.6-7.5 AU/mL) compared to non-transplanted, uninfected naïve subjects (14209 AU/mL, 95% CI: 11261-18836 AU/mL) (p<0.0001). In LT patients, Moderna-evoked seropositivity trend was higher by 23-fold than Pfizer. 2D COVID-19 vaccination elicits a dampened serological response in LT patients. Whether assessing other arms of host immunity combined with higher vaccine dose can better capture and elicit improved immunogenicity in this immunocompromised population warrants investigation.Competing Interest StatementAbbott Diagnostics provided part of the antibody testing reagents. But they did not have any role in the study design, collection, analyses, interpretation of data, drafting manuscript, or in the decision to publish the results. The authors declare no other conflict of interest.Funding StatementThe authors received no financial support for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serum samples from LT recipients vaccinated for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna vaccines or 2D-vaccinated naive (non-transplanted and COVID-19 non-exposed) group were used in this study. They were de-identified, discarded, and remnant blood samples available in the laboratory after routine analysis. This study involved no specific collection of samples. The University of Texas Southwestern Medical Center Institutional Review Board granted a waiver of consent for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to ethical reasons, the data are not publicly available. However, upon request, the data presented in this study can be shared. %U https://www.medrxiv.org/content/medrxiv/early/2021/05/05/2021.04.26.21255926.full.pdf